<!DOCTYPE html>

<html lang="en">
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ka.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/Common.js"></script>
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		var ANIMATION = [];
	</script>
	<style type="text/css">
		body > div { background: #FFF; color: #000;height: 300px; width: 950px; padding:5px 0 0 10px }
	</style>
</head>
<body><div><ol><li>Kaletra [package insert]. North Chicago,Il: AbbVie Inc. <li>Eron JJ, Young B, Cooper DA, et al, for the SWITCHMRK 1 and 2 Investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. <em>Lancet</em>. 2010;375:396-407.</li> <li>National Heart, Lung, and Blood Institute website. ATP III guidelines at-a-glance quick desk reference. National Cholesterol Education Program. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed July 28, 2010. </li></ol> </div></body></html>